Case report of tocilizumab improving outcomes in a patient with cutaneous and systemic plasmacytosis, suggesting a promising treatment option.
Cutaneous and systemic plasmacytosis is a rare lymphoproliferative plasma cell disorder characterized by cutaneous lesions, constitutional symptoms, and polyclonal plasma cell infiltrates. Herein, we describe a middle-aged Vietnamese man diagnosed with cutaneous and systemic plasmacytosis who responded to anti–interleukin-6 receptor antibody tocilizumab and has remained in remission for more than 3 years without tocilizumab-related adverse events.
No takes yet. Share an insight, caveat, or question.
Kondle et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: